Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranibizumab biosimilar - Lupin

Next Previous
Drug Profile

Ranibizumab biosimilar - Lupin

Alternative Names: LUBT-010; RaniEyes; RanluspecTM

Latest Information Update: 05 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lupin
  • Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Wet age-related macular degeneration
  • Preregistration Corneal neovascularisation; Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion
  • Phase III Age-related macular degeneration

Most Recent Events

  • 17 Dec 2025 Phase-III clinical trials in Wet age-related macular degeneration (In the elderly, In adults) in USA (Intravitreous)
  • 17 Dec 2025 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of ranibizumab biosimilar for Wet age-related macular degeneration in European Union
  • 11 Dec 2025 Preregistration for Corneal neovascularisation (In adults, In the elderly) in European Union (Intravitreous )

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top